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Abstract: Tuberculosis (TB) remains a global health emergency, with an estimated 2 billion people
infected across the world, and 1.4 million people dying to this disease every year. Many aspects
of the causative agent, Mycobacterium tuberculosis, make this disease difficult for healthcare and
laboratory researchers to fight against, such as unique pathophysiology, latent infection and long and
complex treatment regimens, thus causing patient non-compliance with the treatment. Development
of new drugs is critical for tackling these problems. Repurposing drugs is a promising strategy for
generating an effective drug treatment whilst circumventing many of the challenges of conventional
drug development. In this regard, the incorporation of immunomodulatory drugs into the standard
regimen to potentiate frontline drugs is found to be highly appealing. Drugs of diverse chemical
classes and drug categories are increasingly being evidenced to possess antitubercular activity, both
in vitro and in vivo. This article explores and discusses the molecular entities that have shown
promise in being repurposed for use in anti-TB adjunctive therapy and aims to provide the most
up-to-date picture of their progress.
Keywords: tuberculosis; drug resistance; repurposing; immunomodulatory drugs; NSAIDs;
adjunctive therapy; potentiator
1. Tuberculosis: The Disease, the Immunobiology and the Available Treatment
Despite the recent resurgence in political will to fight tuberculosis (TB), the disease
remains as a leading cause of death from a single infectious agent around the world [1].
Every year, an estimated 1.2 million deaths are caused by TB in the HIV-negative population
with a further 208,000 deaths from those who are HIV-positive. Roughly a quarter of the
world is infected—around 2 billion—and 10 million new cases are said to develop every
year, making TB still an extremely prevalent disease. Moreover, the disease has a distinct
geographical distribution, with the most heavily burdened countries often being of lower
income, strongly coinciding with where HIV infection rates are rampant too. The milestones
and targets set by The End TB Strategy push public healthcare and interdisciplinary science
capabilities to the limit.
The causative agent of TB is Mycobacterium tuberculosis, a slow-growing acid-fast
bacillus manifesting itself primarily as a respiratory pathogen causing pulmonary disease.
It can also cause extra-pulmonary TB via systemic infection, and its pathogens are capable
of crossing the blood–brain barrier. This dangerous pathogen is required to be handled in a
Biosafety Level 3 environment, and in conjunction with its slow-growing nature, makes
for an especially difficult bacterium to study. Adding to its unique physiology are its
cell wall [2], biofilms [3] and notorious drug efflux pumps [4], which work together to
efficiently ruin many of our attempts to develop drugs against it.
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Granulomas are the iconic immunological host response to TB infection [5]. The struc-
turally organised cluster of macrophages and lymphocytes is the immune system’s most
fundamental strategy for containing the spread of infection and eliminating the entrapped
bacilli [6]. Although granulomas are capable of sterilising infection foci, M. tuberculosis
can enter a state of dormancy in response to stresses making it remarkably more toler-
ant to immune responses as well as antibiotic chemotherapy [6]. The majority of the
infected population is described to be in this state of latent TB infection (LTBI), showing no
overt symptoms.
Reawakening from this persistence state is a slow, stochastic and poorly understood
process. TNF-α is a linchpin of the anti-TB response as it recruits immune cells and drives
the formation and maintenance of granulomas. Transient immunosuppression, for example
in anti-TNF therapy, provides stimulus for bacilli to reawaken and cause active disease [7,8].
Immunosuppressive diseases, such as diabetes mellitus and HIV, are linked with higher
susceptibility to active TB. As much as 10% of the TB-infected population in HIV endemic
regions are estimated to have active disease as a result of co-infection [1].
The nature of TB enhances the development of resistance to antibiotics. Bacilli emerg-
ing from persistence generate a constant influx of cells of varying levels of physiological
resistance, facilitating the selection of genetic resistance. Granulomas also diminish the pen-
etration of antibiotics, exposing the bacilli to a decreased concentration of the drugs too [9].
Finally, it is no surprise that the current gruelling 6-month regimen of rifampicin, isoniazid,
ethambutol and pyrazinamide sees suboptimal compliance, further promoting resistance.
The prospect of vaccines eradicating TB seems far into the future as the latest M72/AS01E
vaccine only provides protection in half of those administered after three years [10], and
efficacy of the BCG vaccine against adult pulmonary disease is highly disputed [11].
Moreover, it took an astonishing 40 years, after the golden era of antibiotic discovery, for
an anti-TB drug with a completely unique mechanism of action to be developed and then
become approved by the FDA [12,13]. It is evident that the low-hanging fruit for novel
antimicrobials has been long picked.
2. The Prospect of Repurposing
In the midst of all these interconnected factors that hinder TB eradication, drug re-
purposing is a prospective strategy. Drugs that are repurposed for TB can fast-track initial
stages of drug development as safety trials, and pharmacokinetic/pharmacodynamic
(PK/PD) testing has been performed during testing for other disease conditions. The
potential reduced financial investments and faster rollouts of novel treatment strategies
make repurposing highly desirable in the light of the new drug development pipeline
drying up. There are numerous leaps forward of repurposing in other fields, as well as
many prospective leads in the repurposing of anti-infectives for TB, such as anti-helminthic
drug pyrvinium pamoate, which protects against extensively drug-resistant TB (XDR-TB)
in murine models [14], and various antibiotic classes, including fluoroquinolones, nitroimi-
dazoles, β-lactam/β-lactamase inhibitor combinations and oxazolidinones. Moxifloxacin
has been successfully repurposed as second-line treatment for TB [15], and several other
fluoroquinolones are in clinical trials to shorten TB treatment or are in pre-clinical devel-
opment [16], whilst novel derivatives from nitroimidazole, pretomanid and delamanid
have been approved for use in TB patients and have numerous late clinical trials aiming
to incorporate them into combination therapies [17]. There has also been a resurgence of
interest in β-lactams owing to the discovery of β-lactamase inhibitors, clavulanate and
avibactam, and they are featured in several clinical trials [18–21]. Although originally for
Gram-positive bacteria, oxazolidinones—linezolid and its derivatives—are in many clinical
trials, with linezolid already approved for use in TB [22]. In addition, the antiparasitic
artemisinin is currently receiving a lot of attention from the research community for its
ability to disrupt signalling that regulates persistence in M. tuberculosis [23–26].
In a disease with such a heavy involvement of immunology as TB infection, the
potential for host-directed therapies (HDTs) is overwhelming [27,28]. The power to reduce
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excessive lung damage and enhance bactericidal capacity of the immune system is immense,
all the while avoiding the risk of resistance seen in antimicrobials. A controlled dampening
of the immune system to stimulate reawakening of the bacteria may be exploited to
predispose the awakening bacteria to elimination by first-line drugs and shorten treatment
due to elimination of the dormant reservoir [29].
Whether repurposing immunomodulatory drugs is a selective leg-up or a silver bullet
will require further investigation and close analysis of our first steps in this approach.
3. Repurposing Immunomodulatory Compounds
There are numerous aspects of inflammation that differentially determine the outcome
of immunity against TB. Excessive inflammation and necrosis can overwhelm the lung’s
ability to repair itself and even spread the infection, whilst too weak of an immune response
will disrupt granuloma integrity and release the bacilli [30]. Little has been elucidated about
what predisposes an infected individual to either extreme of the inflammatory response,
but in the meantime, there have been countless attempts to pharmacologically modulate
and correct the immune response in adjunct therapy alongside the standard anti-TB drug
regimen (see Table 1 for a general overview).
One of the most investigated out of these is vitamin D due to the link between
vitamin D deficiency and TB susceptibility and its potential to stimulate autophagy and
the production of antimicrobial peptides [31]. Another welcome observation of vitamin D
is its direct growth inhibition of mycobacteria in vitro [32]. Being essential for our natural
consumption, vitamins are particularly easy to investigate in clinical trials as they come
with few safety concerns, attributed to the numerous studies on vitamins in host-directed
therapy and countless retrospective studies on vitamin D supplementation [33]. However,
studies show conflicting results on the efficacy of vitamin D in adjunct therapy, with some
showing accelerated sputum culture conversion only in multi-drug-resistant TB (MDR-TB)
patients but not overall in the study [34], whilst others detect no effect whatsoever [35].
Many studies do highlight an improved quality of life for a specific subset of patients,
which perhaps points to us requiring more investigation on patient markers for effective
vitamin D adjunctive therapy, the sensitivity for which retrospective studies are likely
to lack. Despite so much investigation in this area, the future of vitamins in TB is still
unclear. Regardless, it is tempting to make vitamin supplementation a standard procedure
for TB-infected individuals in regions of the world where malnutrition and natural vitamin
deficiencies suppresses the immune system.
Corticosteroids are a clinically important drug class used in modulating the immune
system in other illnesses and have also attracted a lot of attention for potential host-directed
therapy. The more pronounced differential organ-specific effects of corticosteroids may
make it hard to repurpose them for use in a general immunomodulatory adjunct therapy,
however [36]. This leaves corticosteroids to be primarily used for reducing excessive
inflammation in the severest cases of meningitis TB for now, as a study of prednisolone
in HIV-associated pulmonary TB showed no survival benefit but showed a reduction
in clinical complications [36,37]. Their ability to influence anti-TB drug accumulation in
different compartments of the body can perhaps be exploited in a customised organ-specific
therapy for various extrapulmonary foci of TB infection.
3.1. Immunomodulation Is Diverse
Immunomodulatory properties are not exclusive to drugs classically considered as
general-purpose anti-inflammatory drugs. The histone deacetylase inhibitor, phenylbu-
tyrate, used originally for urea cycle disorders, has seen several successful clinical trials that
indicate a diverse array of immunomodulatory functions in TB infection [38–40]. Further-
more, the notorious thalidomide, used originally for morning sickness, has been frequently
investigated for its use in meningitis TB therapy due to its antagonistic effect on TNF-α
for its potential to limit excessive inflammation [41,42]. Though alleviating symptoms, the
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counter-productive T cell co-stimulatory properties of thalidomide and, most importantly,
its teratogenicity restrict its translation of immunomodulatory properties in the clinic [43].
The chemical diversity of molecular entities possessing immunomodulatory potential
repeatedly exceeds expectation. Auranofin is a peculiar molecule consisting of a gold
atom conjugated to a saccharide, used in the treatment of rheumatoid arthritis, which
can make M. tuberculosis prone to reactive oxygen species (ROS) and reactive nitrogen
intermediates (RNI) attack, currently investigated in a phase II trial (NCT02968927). The
concept of repurposing drugs opens our eyes to the opportunity to make better use of our
entire arsenal of therapeutic molecules. Our conventional expectation for what confers
therapeutic efficacy may be limiting our potential to treat disease.
A wilder example is seen in doxycycline. Although originally developed for its effect
on bacteria and not the host, doxycycline in fact exerts a direct effect on human matrix
metalloproteinases. M. tuberculosis infection reprograms the host tissue environment and
causes destruction to lung tissue, making the potential of doxycycline to counteract these
phenomena highly attractive [44]. A mouse model of TB infection demonstrates the potency
of doxycycline in stabilising lung tissue integrity and increasing the concentration of first-
line anti-TB drugs in the lung tissue [45]. A clinical trial investigating its efficacy in humans
has been completed, and its results are awaited (NCT02774993).
A similar effect of optimising drug distribution is seen in drugs used for cardiovascular
disorders. Verapamil, a drug used for treating high blood pressure, potentiates standard
TB therapy in mice, additionally exerting a direct inhibitory effect on M. tuberculosis [46,47].
Its ability to reduce the MIC of bedaquiline in vitro and increase the bioavailability of
bedaquiline in mouse models makes it a very promising drug to follow in the future [48].
The cholesterol-lowering statins show a variety of properties which give them good po-
tential for repurposing in adjunctive TB therapy. The effect of pravastatin on macrophages
phenocopies that of classically activated macrophages, whilst all members of the drug class
exert an inhibitory effect on TB-infected macrophage ex vivo models [49]. Some statins also
show synergy with first-line drugs in vitro and in vivo, highlighting their multi-pronged
effect in inhibiting TB growth. A retrospective analysis reveals protection from LTBI in
statin users [50], and one phase II trial investigating rosuvastatin in adjunctive therapy
is underway (NCT04504851). However, concerns about the detrimental effects on host
immunity arise from cases of rapid progression of bladder cancer upon statin use [51],
as well as the drug interaction with the anti-TB drug rifampicin [44], warranting further
investigation before repurposing is possible [52].
The same study by Magee, M.J. et al. [50] revealed metformin use to also protect against
LTBI, once again highlighting the well-established link between diabetes mellitus and TB
susceptibility [53]. Following from these disease associations, the evidence supporting
metformin use as an adjunctive drug is building in both mouse models [54] and in the
clinic [55,56].
Another large class of drugs being investigated for anti-TB adjunct therapy is the phos-
phodiesterase inhibitors (PDE-I). Unlike non-steroidal anti-inflammatory drugs (NSAIDs),
phosphodiesterase inhibitors target a family of host enzymes that are divergent in func-
tion. Although PDE-I all block the degradation of second messenger intracellular cyclic
nucleotides to modulate intracellular signalling, the distributions of the different phospho-
diesterases is tissue-specific, and thus inhibitors of different isoforms of phosphodiesterase
produce a unique profile of effect. In one experimental model the PDE-5 inhibitor sildenafil
is observed to prolong death in mice without decreasing bacterial burden, whilst PDE-3
inhibitor cilostazol does in fact reduce bacterial load in lungs [57]. This can be somewhat
explained by how PDE-5 is found predominantly in lung tissue and PDE-3 in macrophages
and platelets [58]. In drugs with such varied modulatory effects on intracellular signalling,
it would be important to commence animal model studies promptly to evaluate the net
effect of all the individual effects on different tissues. Overall, various inhibitors of PDE-3,
-4 and -5 have demonstrated excellent anti-TB activity and synergy with frontline drugs in
mouse and rabbit models and are soon to enter clinical trials as adjunct therapy [59–61].
Antibiotics 2021, 10, 91 5 of 13
3.2. Anti-Cancer Drugs
Repurposing for TB therapeutics is recently taking inspiration from cancer therapeu-
tics, which perhaps is no surprise due to the role of immunomodulation at the microenvi-
ronment level in both diseases. Imatinib targets host tyrosine kinases and was originally
designed for Abl kinase-driven cancers, though mouse model experiments of imatinib
against TB show that its immunomodulatory effects are translatable [62]. Indeed, a recent
case was of a chronic myeloid leukaemia patient undergoing imatinib therapy whose latent
TB had reawakened [63]. A phase II trial is scheduled to commence shortly to investigate
this (NCT03891901). TNF-α inhibitors and LT-α inhibitors, highly successful in cancer treat-
ment, also show potential for repurposing, as an in vitro granuloma model reveals their
ability to resuscitate dormant TB via controlled immunosuppression [64]. There is a recent
burst of exploration into similar molecules, such as nilotinib, gefitinib and fostamatinib,
each showing varied mechanisms of action, for example, enhancing autophagy [65–67].
Cancer research also arguably boasts the most innovative strategies in therapeutics.
Biologics contrast the small molecule drugs discussed thus far but have demonstrated
many successes in cancer. Denileukin diftitox, used against T cell lymphomas, is a fusion
protein of diphtheria toxin and human CD25 receptor, targeting regulatory T cells for
killing by the toxin component to revert immunosuppressive microenvironments in a
mouse model [68]. Research here is still in its early stages, and it has been proposed
that these biologics may in fact be detrimental in TB infection [69]. The work needed for
successful repurposing is immense, but these early findings on the potential of biologics in
anti-TB therapeutics may breathe new life into how we approach developing new therapies
against the disease. Chimeric antigen receptor (CAR)-T cell therapy describes the ex vivo
gene editing of antigen receptors of patient T cells before re-introduction into patients for
enhanced immunity in cancers [70]. Perhaps CAR-T cell therapy can be adopted for use in
the treatment of TB.
There remain many drugs of diverse purpose that are investigated for their repurpos-
ing value in isolated pockets of research. Diosmin, used normally for haemorrhoids, was
discovered in silico as a repurposable drug and demonstrates protection in a Drosophila TB
model, also highlighting the potential of in silico methods to find new leads [71]. Lipoxyge-
nase inhibitors were proposed as immunomodulators after inhibition of host lipoxygenase
improved survival in a mouse model [33,72]. Antiviral isoprinosine resuscitates the im-
mune system dampened by viruses during infection and can potentially be repurposed for
use against TB [73]. In addition to phenylbutyrate, histone acetylase inhibitors valproic acid
and vorinostat, originally developed for neurological disorders and cancers, respectively,
show synergy with frontline drugs in a macrophage model [39]. Phenothiazines have been
deemed too toxic in several clinical trials [74,75], whereas the MIC of the thiocarbamate,
disulfuram, was found to be too high. Disulfuram has recently been further repurposed to
act as a copper ion chelator to deliver bactericidal activity in vitro [76].
3.3. Non-Steroidal Anti-Inflammatory Drugs
Non-steroidal anti-inflammatory drugs (NSAIDs) are a large and diverse class of drugs
that inhibit cyclooxygenase (COX) to reduce prostaglandin production, thereby alleviating
inflammation, fever and pain [77]. Although the WHO recommends administering NSAIDs
for TB patients, they are aimed at relieving the joint pain caused by anti-TB drugs and
directly helping with the infection itself. In recent years, there has been a growing body of
science to support the use of NSAIDs in adjunctive therapy, especially as some members
of the NSAIDs chemical class are available as over-the-counter medication, making them
easier to repurpose.
The most studied NSAID currently in TB research is ibuprofen. This common drug
found in most households has been found to demonstrate a direct inhibitory effect in whole-
cell screening assays [78] and most importantly provide protection against TB in mouse
animal models [79,80]. A newer paper calls into question the validity of the disease model
in the latter papers, however, criticising the use of intravenous (IV) infection as opposed
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to a more representative respiratory infection route used in their paper, demonstrating
that ibuprofen and celecoxib are in fact detrimental for immunity against TB [81]. The
author reasoned that an IV infection using an unphysiological thousand-fold higher dose
of M. tuberculosis would trigger massive inflammation which an anti-inflammatory drug
would, of course, alleviate. The importance of the quality of disease models is acutely
emphasised in a complex disease like TB. Nevertheless, we await the results for a phase II
clinical trial investigating the use of ibuprofen as adjunctive therapy in extensively drug-
resistant TB (NCT02781909). The results from this study will be valuable in discerning the
significance of the many conflicting findings of the pre-clinical research.
Aspirin is another common household NSAID which received attention in the TB
research community. Although initially shown to potentiate the first-line drug, pyraz-
inamide, in a murine model [82], its undesirable drug interactions with isoniazid [83]
and lack of significant effect observed in the more powerful rabbit TB model shows little
promise for aspirin as an immune-modulatory adjunctive drug [43]. Instead, aspirin holds
greater potential for use as a general anti-inflammatory drug for a disease driven by ex-
cessive inflammation, such as meningitis TB, as opposed to one which demands a finer
balance of the different arms of immunity as in pulmonary TB. One clinical study showed
aspirin in combination with corticosteroids reduces strokes and mortality in tuberculous
meningitis [84], and we will see the results of a similar ongoing study soon (NCT02237365).
Etoricoxib, meloxicam and celecoxib form the remaining NSAIDs which have been
studied in clinical trials. The results from a recent study attempting to determine the safety
of etoricoxib as an adjunct for the novel H56:IC31 vaccine are eagerly being awaited as we
see the first steps of a vaccine that targets reinfection and relapsing TB infection, as well as
a NSAID used as an immunostimulant for vaccine response (NCT02503839). The results
from the long-completed phase III clinical study on meloxicam in preventing TB-immune
reconstituted inflammatory syndrome (TB-IRIS) have yet to be published (NCT02060006).
Finally, celecoxib was investigated in a phase I ex vivo trial for adjunctive therapy which
showed no effect, though the significance of an ex vivo model is unknown (NCT02602509).
Some NSAIDs which have fallen away from the spotlight are oxyphenbutazone,
diflunisal and bromfenac [85]. Their progression beyond their in vitro inhibitory potential
is thwarted perhaps by concerns about toxicity [86]. The toxicity profile of diclofenac
appears to be deemed too dangerous for its observed synergy in a murine model with
former first-line antibiotic, streptomycin, to warrant further investigation [87].
The host-directed therapeutic effects of NSAIDs vary predominantly via their different
pharmacokinetic properties, as opposed to varying via alternative mechanisms, exerting
differential effects based on tissue location and cell type. Carprofen is an NSAID recently
found to lean strongly towards direct antitubercular-specific mechanisms of action, in
contrast to the majority of NSAIDs, boasting a minimum inhibitory concentration (MIC) of
40 µg/mL, well within the MIC range of most antibiotics [78]. Traditionally, a drug with a
pathogen-directed activity would bring up concerns about the development of resistance.
However, carprofen demonstrates a pleiotropic mechanism of action, disrupting efflux
pumps, biofilms and membrane potentials, which lessens the risk and effect of resistance
mutations [88]. In conjunction with its classical NSAID effects, carprofen proves to be a
promising candidate for further testing in animal models for its potential to simultaneously
revert tolerance to first-line TB drugs through inhibition of efflux pumps, directly inhibit
growth and exert a host-directed immunomodulatory effect. Having been used in human
medicine for over 10 years but later repositioned for veterinary use for commercial reasons,
carprofen should face greater ease in repurposing as an anti-TB adjunct drug [89].
The discovery of more anti-tuberculosis adjunctive drugs and potentiator molecules
may be facilitated by following strategies used in the development of an effective com-
bination therapy against TB. Hypomorphs describe M. tuberculosis strains engineered to
have reduced expression of a gene that is essential for function. Screening a library of
repurposable compounds against various hypomorph strains allows for greater sensitivity
in detecting compounds with inhibitory effects on particular pathways [90]. This may be
Antibiotics 2021, 10, 91 7 of 13
especially important in targeting pathways that are more difficult to observe as having
relevance during initial in vitro whole-cell screens but are critical in vivo, such as mycobac-
terial HsaD. The hsaD (Rv3569c) gene is found to be essential for mycobacterial cholesterol
metabolism within macrophages, and its hypomorphs have been used to identify and
develop novel chemical leads in antibiotic discovery [91], highlighting the potential for a
similar approach to be used to identify candidate repurposed drugs.
As for the more classical NSAIDs, given the role of prostaglandins in antagonising
TNF-α, IL-1β, ROS and RNI, there is obvious potential for NSAIDs enhancing killing of
M. tuberculosis through inhibition of COX [77]. However, the whole picture seems far more
complex as prostaglandins are also essential for reducing early mitochondrial damage
and bias macrophages towards apoptosis instead of necrosis [92]. As apoptosis drives
both innate and adaptive immune defence mechanisms, prostaglandins have effects on
both arms of immunity. Furthermore, some virulent strains of TB can be seen to inhibit
COX-2 production themselves [77]. In the study of such multi-functional drugs against
such a multi-faceted disease, it is critical to use animal models that more closely mimic
the intricacies of human pulmonary TB like cavitating lung granulomas, which the rabbit
or C3HeB/FeJ mouse models achieve, as this would allow the potential of NSAIDs to be
assessed with greater accuracy. Additionally, while NSAIDs have a justified role due to
their antimicrobial mechanisms of action in the proposed adjunctive therapy, the timing of
administration and route of drug delivery would be critical in modulating the immune
response appropriately. Such resource-intensive testing for whether individual TB patients
are appropriate for administration strays far from a simple and standardised drug regimen
for reducing the prevalence of such a widespread disease. Only further research and
clinical testing can help us answer these questions.
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Table 1. Summary table of the most promising immunomodulatory drugs discussed in this literature review currently
under investigation for their potential to be repurposed as an adjunct drug for the standard anti-TB drug regimen.
Drug Class Name Original Indication Delivery Route FDA Approval Clinical Trial Progression Availability Key References
Biologic Denileukin diftitox Cutaneous T celllymphoma IV 1999 – PO [68]
CCB Verapamil Angina Oral 1981 – PO [46,47]
HDACi Phenylbutyrate Urea cycle disorders Oral 1996 NCT01580007 Phase IItrial completed 2018 PO [38–40]
HDACi Valproic acid Epilepsy Oral 1978 – PO [39]
HDACi Vorinostat Cutaneous T celllymphoma Oral 2006 – PO [39]
LOi – Asthma, neoplasms,arthritis – – – – [33,72]
NSAID Aspirin Arthritis, analgesic Oral 1950 NCT02237365 Phase IItrial awaiting results OTC [43,82–84]
NSAID Carprofen Analgesic Oral 1987 – VUO [78,88]
NSAID Celecoxib Arthritis Oral 1998 NCT02602509 Phase Itrial completed PO [33,81]
NSAID Etoricoxib Inflammatorydisorders Oral –
NCT02503839 Phase I
trial underway PO [29,33]
NSAID Ibuprofen Arthritis, analgesic Oral 1974 NCT02781909 Phase IItrial underway OTC [79–82]
NSAID Meloxicam Arthritis Oral 2000 NCT02060006 Phase IIItrial awaiting results PO [33]
PDEi Cilostazol Cardiovasculardisorders Oral 1999 – PO [57–61]
PDEi Sildenafil Erectile dysfunction Oral 1998 – PO [57–61]
Statins Pravastatin Cardiovasculardisorders Oral 1991
NCT04504851 Phase II
trial underway PO [49]
Statins Rosuvastatin Cardiovasculardisorders Oral 2003
NCT04504851 Phase II
trial in planning PO [50]
TC Doxycycline Bacterial infections Oral 1967 NCT02774993 Phase IItrial awaiting results PO [44,45]
TNFi – Autoimmunedisorders – – – – [8]
TKI Fostamatinib Chronic immunethrombocytopenia Oral 2018 – PO [65–67]
TKI Gefitinib Metastatic non-smallcell lung cancer Oral 2003 – PO [65–67]
TKI Imatinib Chronic myeloidleukaemia Oral 2001
NCT03891901 Phase II
trial in planning PO [62,63]
TKI Nilotinib Chronic myeloidleukaemia Oral 2007 – PO [65–67]
Vitamin Vitamin D Vitamin Oral – Several clinicaltrials completed OTC [31–35]
– Auranofin Rheumatoid arthritis Oral 1985 NCT02968927 Phase IItrial awaiting results PO [93]
– Diosmin Haemorrhoids Oral 1 – – – [71]
– Isoprinosine Viral infections Oral – – – [73]
– Thalidomide Leprosy Oral 1998 Several clinicaltrials completed PO [38–40]
Abbreviations: CCB, calcium channel blocker; HDACi, histone deacetylase inhibitor; IV, intravenous; LOi, lipoxygenase inhibitor; NSAID,
non-steroidal anti-inflammatory drug; OTC, over the counter; PDEi, phosphodiesterase inhibitor; PO, prescription-only; TC, tetracycline;
TKI, tyrosine kinase inhibitor; TNFi, tumour necrosis factor inhibitor; VUO, veterinary use only. 1 Also available as topical medication.
4. Conclusions
In the midst of rising antibiotic resistance and the uncertain future for conventional
new drug design, repurposing immunomodulatory drugs has potential to hold tremendous
value for TB research. Despite promising clinical trials in this area, the many conflicting
pieces of evidence leave some key questions unanswered (Figure 1). Are the effects of
immunomodulatory drugs suitable for incorporation into a standardised anti-TB treatment
or should they be reserved for patient-tailored treatment? Can drugs be directly repur-
posed against TB or will drugs have to undergo further chemical modification, thereby
reducing/increasing further challenges? How much of the effect of these repurposed
drugs is host-directed and how much is pathogen-directed? Following this, what are the
long-term off-target/adverse effects on the host and how great is the risk of development
of resistance? Many inquiries remain before repurposed immunomodulatory drugs can
become a standard anti-TB chemotherapy. To tackle the questions that hinder us from
achieving this goal, multi-disciplinary research must be conducted at a greater pace and
scale, and yet still with caution, given the significant potential of immunomodulation to
also cause complexity in TB pathophysiology.
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